Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AAM’s Francer On Tackling Tactics That Hurt Market Access For Gx, Biosimilars

Executive Summary

Association for Accessible Medicines interim CEO and general counsel Jeff Francer, in an interview with Scrip, discusses the industry body’s continued efforts to ensure that generics and biosimilars are not disadvantaged in the US by the brand name industry's commercial tactics or legal/regulatory moves, and outlines the 'enormous progress' made by generic firms on quality.

You may also be interested in...



AAM’s Leonard On Strategizing For Gene Therapies

As ‘hyper personalized’ medicines take hold, generic players need to examine the role they can play in democratizing access to gene therapies alongside complex generics and biosimilars, says AAM president and CEO Dan Leonard.

US Medicare Insulin Demo Could Expand To Other Drugs

Eighty-eight insurers who offer Medicare Part D plans are interested in the demonstration project, which would limit insulin copays to $35.

US Medicare Insulin Demo Could Expand To Other Drugs

Eighty-eight insurers who offer Medicare Part D plans are interested in the demonstration project, which would limit insulin copays to $35.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC141772

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel